Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;16(2):220-7.
doi: 10.4103/2230-8210.93739.

Erythropoietin Use and Abuse

Affiliations
Free PMC article

Erythropoietin Use and Abuse

M Joseph John et al. Indian J Endocrinol Metab. .
Free PMC article

Abstract

Recombinant human erythropoietin (rhEPO) is arguably the most successful therapeutic application of recombinant DNA technology till date. It was isolated in 1977 and the gene decoded in 1985. Since then, it has found varied applications, especially in stimulating erythropoiesis in anemia due to chronic conditions like renal failure, myelodysplasia, infections like HIV, in prematurity, and in reducing peri-operative blood transfusions. The discovery of erythropoietin receptor (EPO-R) and its presence in non-erythroid cells has led to several areas of research. Various types of rhEPO are commercially available today with different dosage schedules and modes of delivery. Their efficacy in stimulating erythropoiesis is dose dependent and differs according to the patient's disease and nutritional status. EPO should be used carefully according to guidelines as unsolicited use can result in serious adverse effects. Because of its capacity to improve oxygenation, it has been abused by athletes participating in endurance sports and detecting this has proved to be a challenge.

Keywords: Abuse; continuous erythropoietin receptor activator; darbepoetin; erythropoietin.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
The mechanism of action of erythropoietin

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Jelkmann W. Erythropoietin after a century of research: Younger than ever. Eur J Haematol. 2007;78:183–205. - PubMed
    1. Bunn HF. End run around epo. N Engl J Med. 2009;361:1901–3. - PubMed
    1. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J. 2003;79:367–76. - PMC - PubMed
    1. Eschbach JW, Haley NR, Adamson JW. The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure. Ann N Y Acad Sci. 1989;554:225–30. - PubMed
    1. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993;44:1149–62. - PubMed
Feedback